Enterovirus D68 (EV-D68) is associated with respiratory disease in children. Between 2014 and 2018, EV-D68 infection was linked to peaks of a polio-like neurologic condition called acute flaccid myelitis (AFM), but currently circulating strains are not. We hypothesized that specific mutations within B3 clade strains impact neurovirulence. Few studies have investigated B3 clade strains, and none have recovered these viruses from cDNA infectious clones to understand how novel mutations in B3 clade strains impact neurovirulence. In this study, we examine the neurovirulence of recovered (r) B3 clade strains in relevant human cell culture and 3D organoid models. We demonstrate that rB3 clade strains replicate efficiently in the permissive RD cell line and in human respiratory epithelial cell lines, with BEAS-2B cells exhibiting greater permissivity than A549 cells. rB3 clade strains infect neural cells, including SH-SY5Y cells, a neuroblastoma cell line, and human spinal cord organoids, which model the cellular heterogeneity of the spinal cord. Immunofluorescence staining confirmed infection, with viral antigen colocalized with neurons. These findings are consistent with previous studies from our laboratory and others on the neurovirulence of clinical isolates of B3 clade strains. Overall, we provide a critical platform for rigorous interrogation of viral determinants of neurovirulence within the B3 clade. IMPORTANCE: Enterovirus D68 (EV-D68) can cause acute flaccid myelitis (AFM), a debilitating neurological condition of the spinal cord in children. Identifying viral determinants of EV-D68 neurovirulence is critical to understanding recent shifts in AFM prevalence; however, these investigations have been limited to a small subset of infectious clones distantly related to currently circulating B3 clade strains. In this study, we examine characteristics of recovered (r)EV-D68 strains from the dominant B3 clade. While all rEV-D68 replicate efficiently in a permissive cell line and in human respiratory epithelial cells, titers varied between strains in cultured neuroblastoma cells. Similarly, all B3 clade strains established infection in human spinal cord organoids, but replication varied between strains. Our study provides an essential platform for investigation into viral mutations within relevant B3 clade strains driving shifts in AFM prevalence.
Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause a polio-like paralysis condition, acute flaccid myelitis (AFM). EV-D68-associated AFM cases waned in the US after 2018, and the reasons for this are unknown. It has recently been demonstrated that EV-D68 containing point mutations in viral structural proteins VP1 and VP3 resulted in decreased paralysis in different neonatal mouse models. However, phenotypes of these mutations in a human multicellular central nervous system (CNS) model are unknown. We hypothesize that mutations in VP1 and VP3 will similarly direct neurotropism in human spinal cord organoids (hSCOs). To investigate this, we recreated viruses with mutations in VP3 (I88V) or VP1 (L1I/N2D/T98A/E283K or L1P/V148A/K282R) and infected hSCOs. We found that VP3 I88V and VP1 L1I/N2D/T98A/E283K resulted in decreased titer and viral protein staining, consistent with attenuated neurovirulence in previously published murine models. We also found through immunofluorescence that VP1 L1P/V148/K282R mutations altered cellular tropism, primarily infecting glial cells rather than neuronal cells. When these mutations were combined, their effects on neurotropism were not additive. Sequence analysis of recently circulating EV-D68 strains reveals that VP3 I88 and VP1 E283 have remained the dominant amino acid residues since 2014, whereas VP1 sites 1, 2, and 98 have higher population diversity, indicating that these residues may be contributing to newly reduced neurovirulence after 2018.
Human Parechovirus A (PeV‐A) is a virus with near‐universal infection by age five; however, neonatal infections can lead to meningoencephalitis, sepsis, and death. Prior to the COVID‐19 pandemic, PeV‐A showed biennial seasonality with late summer peaks, but multiple viruses have had shifted circulation post‐pandemic. PeV‐A is not universally included in neonatal sepsis testing; thus, the frequency and clinical spectrum of PeV‐A neonatal meningoencephalitis are not fully described. We sought to evaluate the epidemiology, seasonality, and clinical presentation of neonatal PeV‐A in the 2024 season. We collected remnant cerebrospinal fluid samples from febrile infants under 60 days at a single children's hospital in Southwestern Pennsylvania and assessed for PeV‐A and enterovirus (EV). Six out of 107 (5.6%) febrile infants were positive for PeV‐A and 24 (22.4%) were positive for EV. PeV‐A infections occurred from June to September. PeV‐A positive patients had a distinct combination of higher maximum temperature, rash, and leukopenia without pleocytosis. None of these infants had severe disease. Systematic surveillance of PeV‐A is required to completely understand ongoing PeV‐A circulation patterns, expected clinical course, and long‐term developmental implications.